Making Way Towards North with Profitability Booster: Transgenomic (NASDAQ:TBIO), Bazaarvoice (NASDAQ:BV)

Transgenomic, Inc. (NASDAQ:TBIO) also making a luring appeal, share price swings at $1.12 with percentage change of 287.01% in most recent trading session. Transgenomic, Inc. (TBIO) (TBIO), recently reported a licensing contract with leading Canadian laboratory services provider LifeLabs, which has selected Transgenomic’s ICE COLD-PCR (ICP) technology as its mutation enrichment platform for cancer testing.

“LifeLabs is among the largest laboratory service providers in North America, and we view their adoption of ICE COLD-PCR as a key validation of both the technology and our commercial model that focuses on licensing to a wide variety of molecular diagnostics partners worldwide,” commented Paul Kinnon, President and Chief Executive Officer of Transgenomic. “We believe that this sizable commercial licensing contract is indicative of the growing traction in the marketplace we have been anticipating, and we believe that it will be followed by additional important ICP contracts going forward.”

The operating profit margin is its sub part that firm has -53.60%. Moving toward returns ratio, TBIO has returns on investment of 176.80% which indicates firm’s investment efficiency or to compare the efficiency of a number of different investments. The firm attains analyst recommendation of 2 on scale of 1-5 with week’s performance of 2.99%. The firm attains analyst recommendation of 2 out of 1-5 scale with week’s performance of 2.99%.

Bazaarvoice, Inc. (NASDAQ:BV) need to consider for profitability analysis, in latest session share price swings at $4.40 with percentage change of -3.30%.

The Co has negative -9.70% profit margins to find consistent trends in a firm’s earnings. Gross profit margin and operating profit margin are its sub parts that firm have 62.40% and -8.30% respectively. BV has returns on investment of -10.20%. The returns on assets were -6% that gives an idea about how efficient management is at using its assets to generate earnings. It has returns on equity of -10.60%, which is measuring profitability by disclosing how much profit generates by BV with the shareholders’ money.

The firm attains analyst recommendation of 1.90 on scale of 1-5 with week’s performance of -8.08%. The firm current ratio calculated as 1.60, this value is acceptable if it lies in 1.3% to 3%. But its varies industry to industry. To strengthen these views, active industry firm has Quick Ratio of 1.60, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 0.20, sometimes its remain same with long term debt to equity ratio.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *